Rabbit hemorrhagic disease virus (RHDV) VLPs have been modified into a tumor vaccine by genetically fusing them with murine topoisomerase IIα (TopIIα) and survivin (Donaldson et al., 2017). Here, TOP2A is linked to neoplasm.